The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...

The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

With that as the backdrop, here's a closer look at three names that could be worth more than Berkshire Hathaway just five ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity, doctors are observing a surge in patients ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side effects.

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...